OM
SPPI

Opaleye Management’s Spectrum Pharmaceuticals Inc SPPI Stock Holding History

Opaleye Management’s Portfolio SPPI Stock Details SPPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-31,000
Closed -$587K – 45
2017
Q4 		$587K Buy
+31,000
New +$562K 0.19% 34

Other funds holding SPPI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management's SPPI Position: Q1 2018 in Review

Opaleye Management sold out of Spectrum Pharmaceuticals Inc (SPPI) in Q1 2018, closing a stake of 31,000 shares — an estimated $587K sold.

Opaleye Management first reported a position in SPPI in Q4 2017 and held it in 1 quarter. The position peaked at $587K in Q4 2017. 161 funds tracked by Wall St. Rank hold SPPI as of Q1 2018.

  • Opaleye Management reported no remaining Spectrum Pharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Opaleye Management sold 31,000 Spectrum Pharmaceuticals Inc shares in Q1 2018, an estimated $587K.
  • Opaleye Management first reported a position in Spectrum Pharmaceuticals Inc in Q4 2017 and held it in 1 quarter.
  • Opaleye Management's Spectrum Pharmaceuticals Inc position peaked at $587K in Q4 2017.
  • 161 funds tracked by Wall St. Rank held Spectrum Pharmaceuticals Inc as of Q1 2018.

Based on Opaleye Management's 13F filing for Q1 2018, filed 14 May 2018.